A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Abroad (travel likely)Recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC) · EGFR-TKI Resistant Mutation · EGFR-TKI Sensitizing Mutation · Germline Mutations · Somatic Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Principal Investigator (Min Huang, Professor)
Study leads
Min Huang, Professor
Study Chair
school of pharmaceutical sciences , SunYat-senU